Nutech gets patent to treat incurable diseases in Malaysia

A technology developed by Nutech Mediworld, the first facility in the world to provide human embryonic stem cell therapy, has been granted the 66th patent in Malaysia for the treatment of various medical conditions.
"The ground-breaking technology has been granted the 66th patent in Malaysia for the treatment of various medical conditions. It is being used for treatments of many incurable diseases such as spinal cord injury, diabetes, cerebral palsy, stroke, Parkinson's and others," Nutech Mediworld Medical Director Geeta Shroff said in a statement here today.
Shroff has developed the technology to isolate human embryonic stem cells, culture them, prepare them for clinical application, and store them in ready-to-use form.

The technology differentiates itself from other stem cell therapies in three major ways - it has universal application; it is available in a ready-to-use form with a shelf life of 6 months and can be transported easily, and it has an easy non-invasive delivery mechanism and can be administered in the simple form of an injection.
Due to these qualities it has the potential to be made readily available in pharmacies across the world, much like insulin, the release said.
"This new patent establishes India as a leader in stem cell therapy as now we have developed a ready-to-use product with a shelf life of six months.

"Due to the enormous health benefits to the population, it is important to make this therapy available globally, as a first line of treatment, to safely and effectively improve the quality of life of patients suffering from conditions presently labelled incurable or terminal," Shroff said.
Over the last 13 years, Nutech Mediworld has treated over 1,300 patients from 51countries. Conditions treated include spinal injuries, multiple sclerosis, Parkinson's disease, diabetes, Lyme disease, cerebral palsy and autism.
Early this year, Shroff's technology was granted its 65th patent in Israel. The technology has already been granted patents in countries like Japan, Singapore, South Korea, USA, Australia, New Zealand.